Case report: Exceptional and durable response to Radium-223 and suspension of androgen deprivation therapy in a metastatic castration-resistant prostate cancer patient
Despite the development of new therapies in the last few years, metastatic prostate cancer (PCa) is still a lethal disease. Radium-223 (Ra-223) is approved for patients with advanced castration-resistant prostate cancer (CRPC) with bone metastases and no visceral disease. However, patients’ outcomes...
| Prif Awduron: | , , , , , , |
|---|---|
| Fformat: | Erthygl |
| Iaith: | English |
| Cyhoeddwyd: |
Frontiers Media S.A.
2024-03-01
|
| Cyfres: | Frontiers in Oncology |
| Pynciau: | |
| Mynediad Ar-lein: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1331643/full |